Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs)
Received 25 September 2017
Accepted for publication 13 December 2017
Published 12 March 2018 Volume 2018:13 Pages 1471—1482
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Alexander Kharlamov
Peer reviewer comments 2
Editor who approved publication: Dr Thomas J Webster
Maxim Shevtsov,1–4 Boris Nikolaev,5 Yaroslav Marchenko,5 Ludmila Yakovleva,5 Nikita Skvortsov,5 Anton Mazur,6 Peter Tolstoy,6 Vyacheslav Ryzhov,7 Gabriele Multhoff2
1Department of Cell Biotechnology, Institute of Cytology of the Russian Academy of Sciences, St Petersburg, Russia; 2Department of Radiation Immuno Oncology, Technische Universität München, Klinikum rechts der Isar, Munich, Germany; 3Department of Biotechnology, Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia; 4Department of Pediatric Neurosurgery, Polenov Russian Scientific Research Institute of Neurosurgery, St Petersburg, Russia; 5Department of Nanomedicine, Research Institute of Highly Pure Biopreparations, St Petersburg, Russia; 6Department of NMR, Saint Petersburg State University, St Petersburg, Russia; 7Department of NMR, NRC “Kurchatov Institute”, Petersburg Nuclear Physics Institute, Gatchina, Russia
Background: Glioblastoma is the most devastating primary brain tumor of the central nervous system in adults. Magnetic nanocarriers may help not only for a targeted delivery of chemotherapeutic agents into the tumor site but also provide contrast enhancing properties for diagnostics using magnetic resonance imaging (MRI).
Methods: Synthesized hybrid chitosan-dextran superparamagnetic nanoparticles (CS-DX-SPIONs) were characterized using transmission electron microscopy (TEM) and relaxometry studies. Nonlinear magnetic response measurements were employed for confirming the superparamagnetic state of particles. Following in vitro analysis of nanoparticles cellular uptake tumor targeting was assessed in the model of the orthotopic glioma in rodents.
Results: CS-DX-SPIONs nanoparticles showed a uniform diameter of 55 nm under TEM and superparamagentic characteristics as determined by T1 (spin-lattice relaxation time) and T2 (spin-spin relaxation time) proton relaxation times. Application of the chitosan increased the charge from +8.9 to +19.3 mV of the dextran-based SPIONs. The nonlinear magnetic response at second harmonic of CS-DX-SPIONs following the slow change of stationary magnetic fields with very low hysteresis evidenced superparamagnetic state of particles at ambient temperatures. Confocal microscopy and flow cytometry studies showed an enhanced internalization of the chitosan-based nanoparticles in U87, C6 glioma and HeLa cells as compared to dextran-coated particles. Cytotoxicity assay demonstrated acceptable toxicity profile of the synthesized nanoparticles up to a concentration of 10 µg/ml. Intravenously administered CS-DX-SPIONs in orthotopic C6 gliomas in rats accumulated in the tumor site as shown by high-resolution MRI (11.0 T). Retention of nanoparticles resulted in a significant contrast enhancement of the tumor image that was accompanied with a dramatic drop in T2 values (P<0.001). Subsequent histological studies proved the accumulation of the nanoparticles inside glioblastoma cells.
Conclusion: Hybrid chitosan-dextran magnetic particles demonstrated high MR contrast enhancing properties for the delineation of the brain tumor. Due to a significant retention of the particles in the tumor an application of the CS-DX-SPIONs could not only improve the tumor imaging but also could allow a targeted delivery of chemotherapeutic agents.
Keywords: brain tumor, glioblastoma, tumor targeting, chitosan, superparamagnetic iron oxide nanoparticles, magnetic resonance imaging
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]